Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system

Thrombosis Research

Volumn 91, Issue 6, 1998, Pages 255-285

  Carmeliet, Peter ^a,b   Collen, Désiré ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adenovirus; Angiogenesis; Atherosclerosis; Cancer; Coagulations; Metalloproteinases; Plasminogen; Reste nosis; Thrombosis

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMINOGEN;

ANGIOGENESIS; ANIMAL MODEL; ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CHRONIC INFLAMMATION; EMBRYO; EMBRYO DEVELOPMENT; HEART INFARCTION; HEMOSTASIS; INFECTION; INTIMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD VESSELS; CELL MOVEMENT; EMBRYONIC AND FETAL DEVELOPMENT; EXTRACELLULAR MATRIX; FETAL DISEASES; GENES, LETHAL; GENETIC PREDISPOSITION TO DISEASE; GRAFT SURVIVAL; HEMORRHAGE; HEMOSTASIS; INFECTION; INFLAMMATION; METALLOENDOPEPTIDASES; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MORPHOGENESIS; MYOCARDIAL ISCHEMIA; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN;

EID: 0032531051     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00122-4     Document Type: Review

References (254)

1. Edgington T.S., Mackman N., Brand K., Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 66:1991;67-79.
2. Camerer E., Kolstø A.B., Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 81:1996;1-41.
3. Petersen L.C., Valentin S., Hedner U. Regulation of the extrinsic pathway system in health and disease. The role of factor VIIa and tissue factor pathway inhibitor Thromb Res. 79:1995;1-47.
4. Davie E.W. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost. 74:1995;1-6.
5. Broze G.J. Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 46:1995;103-112.
6. Esmon C.T. The protein C anticoagulant pathway. Arterioscler Thromb. 12:1992;135-145.
7. Perry D.J. Antithrombin and its inherited deficiencies. Blood Rev. 8:1994;37-55.
8. Altieri D.C. Xa receptor EPR-1. FASEB J. 9:1995;860-865.
9. Coughlin S.R. Molecular mechanisms of thrombin signaling. Semin Hematol. 1:1994;270-277.
10. Soifer S.J., Peters K.G., O'Keefe J., Coughlin S.R. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol. 144:1994;60-69.
11. Luther T., Flossel C., Mackman N., Bierhaus A., Kasper M., Albrecht S., Sage E.H., Iruela Arispe L., Grossmann H., Strohlein A., Zhang Y. Tissue factor expression during human and mouse development. Am J Pathol. 149:1996;101-103.
12. Mueller B.M., Reisfeld R.A., Edgington T.S., Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metas tasis. Proc Natl Acad Sci USA. 89:1992;11832-11836.
13. Mueller B.M., Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 101:1998;1372-1378.
14. Pendurthi U.R., Alok D., Rao L.V. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells. up-regulation of poly(A) polymerase Proc Natl Acad Sci USA. 94(23):1997;12598-12603.
15. Poulsen L.K., Jacobsen N., Sorensen B.B., Bergenhem N.C., Kelly J.D., Foster D.C., Thastrup P., Ezban M., Petersen L.C. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem. 273:1998;6228-6232.
16. Zioncheck T.F., Roy S., Vehar G.A. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem. 267:1992;3561-3564.
17. Masuda M., Nakamura S., Murakami T., Komiyana Y., Takahashi H. Association of tissue factor with a gamma chain homodimer of the IgE receptor type I in cultured human monocytes. Eur J Immunol. 26:1996;2529-2532.
18. Ott I., Fisher E.G., Miyagi Y., Mueller B.M., Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol. 140:1998;1241-1253.
19. Müller M., Albrecht S., Gölfert F., Funk R.H.W., Magdolen V., Flössel C., Luther T. Localization of tissue factor in membrane domains connected with force-generating components of the cytoskeleton. Am J Pathol. in press:1998.
20. Sato Y., Asada Y., Marutsuka K., Hatakeyama K., Kamikubo Y., Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost. 78:1997;1138-1141.
21. Sato Y., Asada Y., Marutsuka K., Hatakeyama K., Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost. 75:1996;389-392.
22. Zhang Y., Deng Y., Luther T., Muller M., Ziegler R., Waldherr R., Stern D.M., Nawroth P.P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 94:1994;1320-1327.
23. Zhang Y., Deng Y., Liliensiek B., Bierhaus A., Greten J., He W., Chen B., Hach-Wunderle V., Waldherr R., Ziegler R., Männet D., Stern D.M., Nawroth P.P. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse Meth-A sarcomas. J Clin Invest. 97:1996;2213-2224.
24. Contrino J., Hair G., Kreutzer D.L., Rickles F.R. In situ detection of tissue factor in vascular endothelial cells. Correlation with the malignant phenotype of human breast disease [see comments] Nat Med. 2:1996;209-215.
25. Roomagi R., Volm M. Tissue factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry. correlation between tissue factor and angiogenesis Int J Cancer. 79:1998;19-22.
26. Ruf W., Mueller B.M. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol. 3:1996;379-384.
27. Shoji M., Hancock W.W., Abe K., Micko C., Casper K.A., Baine R.M., Wilcox J.N., Danave I., Dillehay D.L., Matthews E., Contrino J., Morrissey J.H., Gordon S., Edgington T.S., Kudryk B., Kreutzer D.L., Rickles F.R. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer Am J Pathol. 152:1998;399-411.
28. Ollivier V., Bentolila S., Chabbat J., Hakim J., de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 91:1998;2698-2703.
29. Collen D., Lijnen H.R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 78:1991;3114-3124.
30. Vassalli J.D., Sappino J.D., Belin D. The plasminogen activator/plasmin system. J Clin Invest. 88:1991;1067-1072.
31. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma. Its role in thrombotic disease Thromb Haemost. 74:1995;71-76.
32. Schneiderman J., Loskutoff D.J. Plasminogen activator inhibitors. Trends Cardiovasc Med. 1:1991;99-102.
33. Lawrence D.A., Ginsburg D. Plasminogen activator inhibitors. Roberts H.R., High K.A. Molecular Biology of Thrombosis and Hemostasis. 1995;517-543 Marcel Dekker, New York.
34. Hajjar K.A. Cellular receptors in the regulation of plasmin generation. Thromb Haemost. 74:1995;294-301.
35. Plow E.F., Herren T., Redlitz A., Miles L.A., Hoover Plow J.L. The cell biology of the plasminogen system. FASEB J. 9:1995;939-945.
36. Vassalli J.D. The urokinase receptor. Fibrinolysis. 8(Suppl 1):1994;172-181.
37. Blasi F., Conese M., Moller L.B., Pedersen N., Cavallaro U., Cubellis M.V., Fazioli F., Hernandez-Marrero L., Limongi P., Munoz-Canoves P., Resnati M., Rüttininen L., Sidenius N., Soravia E., Soria M.R., Stopelli M.P., Talarico D., Teesalu T., Valamonica S. The urokinase receptor. structure, regulation and inhibitor-mediated internalization Fibrinolysis. 8(Suppl 1):1994;182-188.
38. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 269:1994;32380-32388.
39. Stefansson S., Lawrence D.A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta3 binding to vitronectin. Nature. 383(6599):1996;441-443.
40. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated adhesion and release? J Cell Biol. 134:1996;1563-1571.
41. Chapman H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 9:1997;714-724.
42. Saksela O., Rifkin D. Cell-associated plasminogen activation. Regulation and physiological function Annu Rev Cell Biol. 4:1988;93-126.
43. Chapman H.A. Jr., Stone O.L. Co-operation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J. 222:1984;721-728.
44. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med. 6:1993;244-250.
45. Andreasen P.A., Sottrup Jensen L, Kjoller L., Nykjaer A., Moestrup S.K., Petersen C.M., Gliemann J. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 338:1994;239-245.
46. Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop Scand. 66(Suppl 256):1995;55-60.
47. Dollery C.M., McEwan J.R., Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res. 77:1995;863-868.
48. Mignatti P., Rifkin D.B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 49:1996;117-137.
49. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6:1990;121-125.
50. Jenkins G.M., Crow M.T., Bilato C., Gluzband Y., Ryu W.S., Li Z., Stetler-Stevenson W., Nater C., Froehlich J.P., Lakatta E.G., Gheng L. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation. 97:1998;82-90.
51. Sato H., Okada Y., Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thromb Haemost. 78:1997;497-500.
52. Apte S.S., Fukai N., Beier D.R., Olsen B.R. The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. J Biol Chem. 272:1997;25511-25517.
53. Mattei M.G., Roeckel N., Olsen B.R., Apte S.S. Genes of the membrane-type matrix metalloproteinase (MT-MMP) gene family, MMP14, MMP15, and MMP16, localize to human chromosomes 14, 16, and 8, respectively. Genomics. 40:1997;168-169.
54. Llano E., Pendas A.M., Knauper V., Sorsa T., Salo T., Salido E., Murphy G., Simmer J.P., Barlett J.D., Lopez-Otin C. Identification and structural and functional characterization of human enamylysin (MMP-20). Biochemistry. 36:1997;15101-15108.
55. Sedlacek R., Mauch S., Kolb B., Schatzlein C., Eibel H., Peter H.H., Schmitt J., Krawinkel U. Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology. 198:1998;408-423.
56. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases. structure, regulation and biological functions Eur J Cell Biol. 74(2):1997;111-122.
57. Carmeliet P., Moons L., Lijnen R., Baes M., Crawley J., Lemaître V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., Collen D. Urokinase-generated plasmin is a candidate activator of matrix metalloproteinases during a therosclerotic aneurysm formation. Nature Genetics. 17:1997;439-446.
58. Suzuki M., Raab G., Moses M.A., Fernandez C.A., Klagsbrun M. Matrix metalloprotein- ase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 272:1997;31730-31737.
59. Preece G., Murphy G., Ager A. Metalloproteinase-mediated regulation of L-selectin levels of leukocytes. J Biol Chem. 271:1996;11634-11640.
60. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 182:1996;1777-1783.
61. Black R.A., Rauch C.T., Kozlosky C., Peshon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Ceretti D.P. A metalloproteinase disintegrin that releases tumor-necrosis factor-alpha from cells. Nature. 385:1997;729-733.
62. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
63. Carmeliet P., Collen D. Vascular development and disorders. Molecular analysis and pathogenetic insights Kidney Int. 53:1998;1519-1549.
64. Nehls V., Drenckhahn D. The versatility of microvascular pericytes. From mesenchyme to smooth muscle? Histochemistry. 99:1993;1-12.
65. Beck L., D'Amore P. Vascular development. cellular and molecular recognition FASEB J. 11:1997;365-373.
66. D'Amore P.A., Smith S.R. Growth factor effects on cells of the vascular wall. A survey Growth Factors. 8:1993;61-75.
67. Bugge T.H., Xiao Q., Kombrinck K.W., Flick M.J., Holmback K., Danton M.J., Colbert M.C., Witte D.P., Fujikawa K., Davie E.W., Degen J.L. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiat or of blood coagulation. Proc Natl Acad Sci USA. 93(13):1996;6258-6263.
68. Carmeliet P., Mackman N., Moons L., Luther T., Gressens P., Van Vlaenderen I., Demunck H., Kasper M., Breier G., Evrard P., Müller M., Risau W., Edgington T., Collen D. Role of tissue factor in embryonic blood vessel development. Nature. 383:1996;73-75.
69. Toomey J.R., Kratzer K.E., Lasky N.M., Stanton J.J., Broze G.J. Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood. 88:1996;1583-1587.
70. Toomey J.R., Kratzer K.E., Lasky N.M., Broze G.J.J. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA. 94:1997;6922-6926.
71. Hirschi K.K., d'Amore P.A. Pericytes in the microvasculature. Cardiovasc Res. 32:1996;687-698.
72. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., Pan Y.C., Olander J.V., Connolly D.T., Stern D. Vascular permeability factor. a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration J Exp Med. 172:1990;1535-1545.
73. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews. 18:1997;4-25.
74. Grosskreutz C.L., Anand-Apte B., Terman B., Quinn T.P., D'Amore P.A. Vascular endothelial growth factor (VEGF) is a chemoattractant for vascular smooth muscle cells (SMC). Invest Opthalmol Vis Sci. 37:1996;5470-5475.
75. Takagi H., King G.L., Aiello L.P. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes. 45:1996;1016-1023.
76. Nomura M., Yamagishi S., Harada S., Hayashi Y., Tamashima T., Yamashita J., Yamamoto H. Possible participation of autocrine and paracrine vascular endothelial gorwth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem. 270:1995;28316-28324.
77. Parry G.C., Erlich J.H., Carmeliet P., Luther T., Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 101:1998;560-569.
78. Rosen E., Chan J.Y., Esohe I., Clotman F., Vlasuk G., Albrecht S., Lissens A., Luther T., Jalbert L., Schoonjans L., Moons L. Collen D, Castellino FJ, Carmeliet P. Factor VII deficient mice develop normally but suffer fatal perinatal bleeding. Nature. 390:1997;290-294.
79. Cui J., O'Shea K.S., Purkayastha A., Saunders T.L., Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 384:1996;66-68.
80. Connolly A.J., Ishihara H., Kahn M.L., Farese R.V. Jr., Coughlin S.R. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 381:1996;516-519.
81. Suh T.T., Holmback K., Jensen N.J., Daugherty C.C., Small K., Simon D.I., Potter S., Degen J.L. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9:1995;2020-2033.
82. Shivdasani R.A., Rosenblatt M.F., Zucker Franklin D, Jackson C.W., Hunt P., Saris C.J., Orkin S.H. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 81:1995;695-704.
83. Gasic G.P., Arenas C.P., Gasic T.B., Gasic G.J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA. 89:1992;2317-2320.
84. Feng N.K., Yang Y.C., Huang S.C., Ou J.T. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest. 98:1996;1493-1501.
85. Ross R., Raines E.W., Bowen Pope DF The biology of platelet-derived growth factor. Cell. 46:1986;155-169.
86. Ettelaie C., James N.J., Wilbourn B., Adam J.M., Naseem K.M., Bruckdorfer K.R. The mechanism of inhibition of factor III (tissue factor) a ctivity by apolipoprotein B-100L protein-protein interactions. Arterioscler Thromb Vasc Biol. 16:1996;639-645.
87. Fan Z., Larson P.J., Bognacki J., Raghunath P.T., Tomaszewski J.E., Kuo A., Canziani G., Chaiken I., Cines D.B., Higazi A.A. Tissue factor regulates plasminogen binding and activation. Blood. 91:1998;1987-1998.
88. Huang Z.F., Higuchi D., Lasky N., Broze G.J.J. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood. 90:1997;944-951.
89. Ishihara H., Connolly A.J., Zeng D., Kahn M.L., Zheng Y.W., Timmons C., Tram T., Coughlin S.R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 386:1997;502-506.
90. Darrow A.L., Fung-Leung W.P., Ye R.D., Santulli R.J., Cheung W.M., Derian C.K., Burns C.L., Damiano B.P., Zhou L., Keenan C.M., Peterson P.A., Andrade-Gordon P. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost. 76:1996;860-866.
91. Healy A.M., Rayburn H.B., Rosenberg R.D., Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality i n mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA. 92:1995;850-854.
92. Jalbert L., Rosen E.D., Moons L., Chan J.C.Y., Carmeliet P., Castellino F.J., Collen D. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest. in press:1998.
93. Bi L., Lawler A.M., Antonarakis S.E., High K.A., Gearhart J.D., Kazazian H.H. Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 10:1995;119-121.
94. Kung S.H., Hagstrom N.D.C., Jen Tai S., Lin H.F., Stafford D.W., High K.A. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 91:1998;784-790.
95. Wang L., Zoppe M., Hackeng T.M., Griffin J.H., Lee K.F., Verma I.M. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci USA. 94:1997;11563-11566.
96. Tuddenham E.G., Pemberton S., Cooper D.N. Inherited factor VII deficiency. genetics and molecular pathology Thromb Haemost. 74:1995;313-321.
97. Hoyer L.W. Hemophilia A. N Engl J Med. 330:1996;38-47.
98. Snyder R.O., Miao C.H., Patijn G.A., Spratt S.K., Danos O., Nagy D., Gown A.M., Winther B., Meuse L., Cohen L.K., Thompson A.R., Kay M.A. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 16:1997;270-276.
99. al Mondhiry H., Ehmann W.C. Congenital afibrinogenemia. Am J Hematol. 46:1994;343-347.
100. Fay W.P., Shapiro A.D., Shih J.L., Schleef R.R., Ginsburg D. Brief report. complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation N Engl J Med. 327:1992;1729-1733.
101. Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev. 3:1989;11-17.
102. Elliott M.J., Faulkner Jones B.E., Stanton H., Hamilton J.A., Metcalf D. Plasminogen activator in granulocyte-macrophage-CSF transgenic mice. J Immunol. 149:1992;3678-3681.
103. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., van den Oord J.J., De Mol M., Mulligan R.C., Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest. 92:1993;2756-2760.
104. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 368:1994;419-424.
105. Carmeliet P., Bouche A., De Clercq C., Janssen S., Pollefeyt S., Wyns S., Mulligan R.C., Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci. 748:1995;367-381.
106. Ploplis V.A., Carmeliet P., Vazirzadeh S., Van Vlaenderen I., Moons L., Plow E.F., Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 92:1995;2585-2593.
107. Bugge T.H., Flick M.J., Daugherty C.C., Degen J.L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9:1995;794-807.
108. Dewerchin M., Nuffelen A.V., Wallays G., Bouche A., Moons L., Carmeliet P., Mulligan R.C., Collen D. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest. 97:1996;870-878.
109. Bugge T.H., Flick M.J., Danton M.J., Daugherty C.C., Romer J., Dano K., Carmeliet P., Collen D., Degen J.L. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of it s receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA. 93:1996;5899-5904.
110. Romer J., Bugge T.H., Pyke C., Lund L.R., Flick M.J., Degen J.L., Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med. 2:1996;287-292.
111. Kitching A.R., Holdsworth S.R., Ploplis V., Plow E., Collen D., Carmeliet P., Tipping P. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med. 5:1997;963-968.
112. Carmeliet P., Moons L., Ploplis V., Plow E.F., Collen D. Impaired arterial neointima formation in mice with disruption of the plasmin ogen gene. J Clin Invest. 99:1997;200-208.
113. Farrehi P.M., Ozaki C.K., Carmeliet P., Fay W.P. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 97:1998;1002-1008.
114. Carmeliet P., Kieckens L., Schoonjans L.et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest. 92:1993;2746-2755.
115. Carmeliet P., Stassen J.M., Meidell R., Collen D., Gerard R. Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice. Blood. 90:1997;1527-1534.
116. Liu A.C., Lawn R.M. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Med. 4:1994;40-44.
117. Palabrica T.M., Liu A.C., Aronovitz M.J., Furie B., Lawn R.M., Furie B.C. Antifibrinolytic activity of apolipoprotein(a) in vivo. Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis [published erratum appears in Nat Med 1995;1:598] Nat Med. 1:1995;256-259.
118. Weiler-Guettler H., Christie P.D., Beeler D.L., Healy A.M., Hancock W.W., Rayburn H., Edelberg J.M., Rosenberg R.D. A targeted point mutation in thrombomodulin generates viable mice aprothrombotic state. J Clin Invest. 101:1998;1983-1991.
119. Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S.K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 86(Suppl III):1992;47-52.
120. Clowes A.W., Reidy M.A. Prevention of stenosis after vascular reconstruction. Pharmacologic control of intimal hyperplasia-a review J Vasc Surg. 13:1991;885-891.
121. Schwartz S.M., Reidy M.A., O'Brien E.R. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost. 74:1995;541-551.
122. Kakuta T., Currier J.W., Haudenschild C.C., Ryan T.J., Faxon D.P. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation. 89:1994;2809-2815.
123. Carmeliet P., Moons L., Stassen J.M., van den Oord J.J., Declerq C., Kockx M., Collen D. A model for arterial neointima formation using perivascular electric injury in mice. Am J Pathol. 150:1997;761-777.
124. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, restenosis, atherosclerosis and hemostasis. Cardiovasc Res. In Press 1998.
125. van Leeuwen R.T. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis. 10:1996;59-74.
126. Carmeliet P., Collen D. Gene manipulation and transfer of the plasminogen system and coagulation system in mice. Sem Thromb Hemost. 22:1996;525-542.
127. Celentano D.C., Frishman W.H. Matrix metalloproteinases and coronary artery disease. a novel therapeutic target J Clin Pharmacol. 37:1997;991-1000.
128. Simpson A.J., Booth N.A., Moore N.R., Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol. 44:1991;139-143.
129. Clowes A.W., Clowes M.M., Au Y.P., Reidy M.A., Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 67:1990;61-67.
130. Reidy M.A., Irvin C., Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res. 78:1996;405-414.
131. Fearns C., Samad F., Loskutoff D.J. Synthesis and localization of PAI-1 in the vessel wall. van Hinsbergh V.W.M., Vadas M.A., Harlan J. Advances in Vascular Biology. 1996;207-227 Gordon and Breach Publishers, Camberwell, Victoria, Australia.
132. Carmeliet P., Moons L., Herbert J.-M., Crawley J., Lupu F., Lijnen R., Collen D. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice. Circ Res. 81:1997;829-839.
133. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Collen D., Gerard R.D. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191.
134. Newman K.M., Jean Claude J., Li H., Scholes J.V., Ogata Y., Nagase H., Tilson M.D. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg. 20:1994;814-820.
135. Galis Z.S., Sukhova G.K., Kranzhöfer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA. 92:1995;402-406.
136. Galis Z.S., Muszynski M., Sukhova G.K., Simon Morrissey E., Unemori E.N., Lark M.W., Amento E., Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzy mes required for extracellular matrix digestion. Circ Res. 75:1994;181-189.
137. Halpert I., Sires U.I., Roby J.D., Potter Perigo S., Wight T.N., Shapiro S.D., Welgus H.G., Wickline S.A., Parks W.C. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atheros clerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA. 93:1996;9748-9753.
138. Irizarry E., Newman K.M., Gandhi R.H., Nackman G.B., Halpern V., Wishner S., Scholes J.V., Tilson M.D. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res. 54:1993;571-574.
139. Sakalihasan N., Delvenne P., Nusgens B.V., Limet R., Lapiere C.M. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg. 24:1996;127-133.
140. Moons L, Shi V, Ploplis V, Plow E, Haber E, Collen D, Carmeliet P. Reduced transplant arteriosclerosis in plasminogen deficient mice. J Clin Invest. In Press 1998.
141. Carmeliet P., Moons L., Dewerchin M., Rosenberg S., Herbert J.M., Lupu F., Collen D. Receptor-independent role of urokinase-type plasminogen activator in arterial wound healing and intima formation in mice. J Cell Biol. 140:1998;233-245.
142. Herbert J.M., Lamarche I., Carmeliet P. Urokinase- and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J Biol Chem. 272:1997;23585-23591.
143. Lijnen R, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Plasminogen/plasmin and matrix metalloproteinase system function after vascular injury in mice with targeted inactivation of fibrinolytic genes. Arterioscl Thromb Vasc Biol. In Press 1998.
144. Lucas A., Liu L., Macen J., Nash P., Dai E., Stewart M., Graham K., Etches W., Boshkov L., Nation P.L., Humen D., Lundstrom-Hobman M., McFadden G. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation. 94:1996;2890-2900.
145. Ross R. The pathogenesis of atherosclerosis. a perspective for the 1990s Nature. 362:1993;2844-2850.
146. Fuster V. Mechanisms leading to myocardial infarction. insights from studies of vascular biology Circulation. 90:1994;2126-2146.
147. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
148. Belkin M., Donaldson M.C., Whittemore A.D. Abdominal aortic aneurysms. Curr Opin Cardiol. 9:1994;581-590.
149. Ernst C.B. Abdominal aortic aneurysm. N Engl J Med. 328:1993;1167-1172.
150. Halloran B.G., Baxter B.T. Pathogenesis of aneurysms. Semin Vasc Surg. 8:1995;85-92.
151. Juhan-Vague I., Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol. 2:1992;427-438.
152. Hamsten A., Eriksson P. Fibrinolysis and atherosclerosis. an update Fibrinolysis. 8(Suppl 1):1994;253-262.
153. Schneiderman J., Sawdey M.S., Keeton M.R., Bordin G.M., Bernstein E.F., Dilley R.B., Loskutoff D.J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 89:1992;6998-7002.
154. Hamsten A., de Faire U., Walldius G., Dahlen G., Szamosi A., Landou C., Blomback M., Wiman B. Plasminogen activator inhibitor in plasma. Risk factor for recurrent myocardial infarction Lancet. 2:1987;3-9.
155. Loskutoff D.J., Samad F. The adipocyte and hemostatic balance in obesity. Studies of PAI-1 Arterioscl Thromb Vasc Biol. 18:1998;1-6.
156. Schneiderman J., Bordin G.M., Engelberg I., Adar R., Seiffert D., Thinnes T., Bernstein E.F., Dilley R.B., Loskutoff D.J. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest. 96:1995;639-645.
157. Lupu F., Heim D.A., Bachmann F., Hurni M., Kakkar V.V., Kruithof E.K. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 15:1995;1444-1455.
158. Plump A.S., Smith J.D., Hayek T., Aalto Setala K, Walsh A., Verstuyft J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
159. Xiao Q., Danton M.J.S., Witte D.P., Kowala M.C., Valentine M.T., Bugge T.H., Degen J.L. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA. 94:1997;10335-10340.
160. Xiao Q., Danton M.J., Witte D.P., Kowala M.C., Valentine M.T., Degen J.L. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 101:1998;1184-1194.
161. Ernst E., Resch K.L. Fibrinogen as a cardiovascular risk factor. A meta-analysis and review of the litterature Ann Intern Med. 118:1993;956-963.
162. Chapman H.A. Jr., Stone O.L., Vavrin Z. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. J Clin Invest. 73:1984;806-815.
163. Shi C., Russell M.E., Bianchi C., Newell J.B., Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res. 75:1994;199-207.
164. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure. Relation to ventricular and myocyte function Circ Res. 82:1998;482-495.
165. Tyagi S.C. Extracellular matrix dynamics in heart failure. A prospect for gene therapy J Cell Biochem. 68:1998;403-410.
166. Funck R.C., Wilke A., Rupp H., Brilla C.G. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol. 432:1997;35-44.
167. Robert V., Besse S., Sabri A., Silvestre J.S., Assayag P., Nguygen V.T., Swynghedauw B., Delcayre C. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest. 76:1997;729-738.
168. Booz G.W., Baker K.M. Molecular signaling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 30:1995;537-543.
169. Cleutjens J.P., Verluyten M.J., Smiths J.F., Daemen M.J. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 147:1995;325-338.
170. Brilla C.G., Rupp H. Myocardial collagen matrix remodeling and congestive heart failure. Cardiologia. 39(Suppl 1):1994;389-393.
171. Schaper W., Ito W.D. Molecular mechanisms of coronary collateral vessel growth. Circ Res. 79:1996;911-919.
172. Bacharach E., Itin A., Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci USA. 89:1992;10686-10690.
173. Pepper M.S., Sappino A.P., Montesano R., Orci L., Vassalli J.-D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol. 153:1992;129-139.
174. Pepper M.S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Comm. 181:1991;902-906.
175. Pepper M.S., Ferrara N., Orci L., Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm. 189:1992;824-831.
176. Wilting J., Christ B. Embryonic angiogenesis. A review Naturwissenschaften. 83:1996;153-164.
177. Kao W.W., Kao C.W., Kaufman A.H., Kombrinck K.W., Converse R.L., Good W.V., Bugge T.H., Degen J.L. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice. Invest Opthalmol Vis Sci. 39:1998;502-508.
178. Shapiro R.L., Duquette J.G., Roses D.F., Nunes I., Harris M.N., Kamino H., Wilson E.L., Rifkin D.B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (u-PA)-deficient and wild type mice. Cellular blue nevi invade but do not progress to malignant melanoma in u-PA-deficient animals Cancer Res. 56:1996;3597-3604.
179. Bugge T.H., Kombrinck K.W., Xiao Q., Holmbäck K., Daugherty C.C., Witte C.P., Degen J.L. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood. 90:1997;4522-4531.
180. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1995;1029-1039.
181. Thompson W.D., Smith E.B., Stirk C.M., Wang J. Fibrin degradation products in growth stimulatory extracts of pathological lesions. Blood Coagul Fibrinolysis. 4:1993;113-115.
182. Nagy J.A., Masse E.M., Herzberg K.T., Meyers M.S., Yeo K.T., Yeo T.K., Sioussat T.M., Dvorak H.F. Pathogenesis of ascites tumor growth. vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation Cancer Res. 55:1995;360-368.
183. Nagy J.A., Meyers M.S., Masse E.M., Herzberg K.T., Dvorak H.D. Pathogenesis of ascites tumor growth. Fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity Cancer Res. 55:1995;369-375.
184. Sabapathy K.T., Pepper M.S., Kiefer F., Möhel-Steinlein U., Tacchini-Cottier F., Fetka I., Breier G., Risau W., Carmeliet P., Montesano R., Wagner E.F. Polyoma middle-T induced vascular tumor formation. the role of the plasminogen activator/plasmin system J Cell Biol. 137:1997;953-963.
185. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin. A novel angiogenesis inhibitor that mediates the suppresion of metastases by a Lewis lung carcinoma Cell. 79:1994;315-328.
186. Cao Y., Ji R.W., Davidson D., Schaller J., Marti D., Sohndel S.G., McCance M.S., O'Reilly M.S., Llinas M., Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative acitivty on endothelial cells J Biol Chem. 271:1996;29461-29467.
187. Cao Y., Chen A., Seong Soo A., Richard-Weidong J., Davidson D., Cao Y., Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 272:1997;22924-22928.
188. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692.
189. Dong Z., Kumar R., Yang X., Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 88:1997;801-810.
190. Stathakis P., Fitzgerald M., Matthias L.J., Chesterman C.N., Hogg P.J. Generation of angiostatin by reduction and proteolysis by plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem. 272:1997;20641-20645.
191. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of metastases. Balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med. 1:1995;149-153.
192. Mudgett J.S., Hutchinson N.I., Chartrain N.A., Forsyth A.J., McDonnell J., Singer I.I., Bayne E.K., Flanagan J., Kawka D., Shen C.F., Stevens K., Chen H., Trumbauer M., Visco D.M. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 41:1998;110-121.
193. Wilson C., Heppner K.J., Labosky P.A., Hogan B.L.M., Matrisian L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA. 94:1997;1402-1407.
194. Itoh T., Tanioka M., Yoshida H., Yoshioda T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1998;1048-1051.
195. Shipley J.M., Wesselschmidt R.L., Kobayashi D.K., Ley T.J., Shapiro S.D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA. 93:1996;3942-3946.
196. Nothnick W.B., Soloway P., Curry T.E. Assessment of the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) during the preovula tory period in female mice lacking a functional TIMP-1 gene. Biol Reprod. 56:1997;1181-1188.
197. Soloway P.D., Alexander C.M., Werb Z., Jaenish R. Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. Oncogene. 13:1996;2307-2314.
198. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrhophic chondrocytes. Cell. 93:1998;411-422.
199. Vu T.H., Werb Z. Gelatinase B. Structure, regulation, and function Parks W.C., Mecham R.P. Matrix Metalloproteinases. 1998;715-748 Academic Press, San Diego.
200. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. J Biol Chem. 271:1996;10079-10086.
201. Xing R.H., Rabbani S.A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer. 67:1996;423-429.
202. Ossowski L. Invasion of connective tissue by human carcinoma cell lines. Requirement for urokinase, urokinase receptor, and interstitial collagenase Cancer Res. 52:1992;6754-6760.
203. Dano K., Behrendt N., Brünner N., Ellis V., Ploug M., Pyke C. The urokinase-receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 8:1994;189-203.
204. Schmitt M., Wilhelm O., Janicke F., Magdolen V., Reuning U., Ohi H., Moniwa N., Kobayashi H., Weidle U., Graeff H. Urokinase-type plasminogen acivator (u-PA) and its receptor (CD87). A new target in tumor invasion and metastasis J Obstet Gynacol. 21:1995;151-165.
205. Ossowski L., Russo Payne H, Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies. The effect on dissemination of a human tumor in the nude mouse Cancer Res. 51:1991;274-281.
206. Fazioli F., Blasi F. Urokinase-type plasminogen activator and its receptor. New targets for anti-metastatic therapy? Trends Pharmacol Sci. 15:1994;25-29.
207. Donati M.D. Cancer and thrombosis. From phlegmasia alba dolens to transgenic mice Thromb Haemost. 74:1995;278-281.
208. Eitzman D.T., Krauss J.C., Shen T., Cui J., Ginsburg D. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood. 87:1996;4718-4722.
209. Pappot H., Gardsvoll H., Romer J., Pedersen A.N., Grondahl Hansen J., Pyke C., Brunner N. Plasminogen activator inhibitor type 1 in cancer. Therapeutic and prognostic implications Biol Chem Hoppe Seyler. 376:1995;259-267.
210. Montesano R., Pepper M.S., Möhle-Steinlein U., Risau W., Wagner E.F. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing middle T oncogene. Cell. 62:1990;435-445.
211. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:1995;27-31.
212. Bajou K., Noel A., Gerard R., Skobe M., Brunner N., Holst-Hansen C., Fusenig R., Carmeliet P., Collen D., Foidart J.M. Role of PAI-1 in tumor angiogenesis. Nature Med. in press:1998.
213. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and met astasis. Cancer Metastasis Rev. 14:1995;351-362.
214. Ray J.M., Stetler-Stevenson W.G. The role of matrix metalloproteinases and their inhibitors in tumor invasion, metastasis and angio genesis. Eur Resp J. 7:1994;2062-2072.
215. Seiki M. Membrane type-matrix metalloproteinase and tumor invasion. Curr Top Microbiol Immunol. 213:1996;23-32.
216. Rouyer N., Wolf C., Chenard M.P., Rio M.C., Chambon P., Bellocq J.P., Basset P. Stromelysin-3 gene expression in human cancer. an overview Invasion Metastasis. 14:1994;946-953.
217. Masson R., Lefebvre O., Noel A., Fahime M.E., Chenard M.P., Wendling C., Kebers F., LeMeur M., Dierich A., Foidart J.M., Basset P., Rio M.C. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial malignancy. J Cell Biol. 140:1998;1535-1541.
218. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 370:1994;61-65.
219. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:1996;683-693.
220. Sympson C.J., Talhouk R.S., Alexander C.M., Chin J.R., Clift S.M., Bissel M.J. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol. 125:1994;681-693.
221. Alexander C.M., Howard E.W., Bissell M.J., Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biol. 135:1996;1669-1677.
222. Streuli C.H., Schmidhauser N., Bailey P., Yurchenco A.P., Skubitz C., Roskelley C., Bissel M.J. Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol. 129:1995;591-603.
223. Sympson C.J., Bissell M.J., Werb Z. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Sem Cancer Biol. 3:1995;159-163.
224. Witty J.P., Wright J.H., Matrisian L.M. Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development. Mol Biol Cell. 6:1995;1287-1303.
225. Alexander C.M., Werb Z. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. J Cell Biol. 118:1992;727-739.
226. Martin D.C., Ruther U., Sanchez Sweatman O.H., Orr F.W., Khokha R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIM P-1 transgenic mice. Oncogene. 13:1996;569-576.
227. Kruger A., Fata J.E., Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood. 90:1997;1993-2000.
228. Boudreau N., Sympson C.J., Werb Z., Bissell M.J. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science. 267:1995;891-893.
229. Boudreau N, Myers C, Bissell MJ. Trends Cell Biol 1995;5:1-5.
230. Sappino A.-P., Huarte J., Vassalli J.D., Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest. 87:1991;962-970.
231. Tomooka S., Border W.A., Marshall B.C., Noble N.A. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 42:1992;1462-1469.
232. Yamamoto K., Loskutoff D.J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest. 97:1996;2440-2451.
233. Yamamoto K., Loskutoff D.J. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am J Pathol. 151:1997;725-734.
234. Bertozzi P., Astedt B., Zenzius L., Lynch K., LeMaire F., Zapol W., Chapman H.A. Jr. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome [see comments]. N Engl J Med. 322:1990;890-897.
235. Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T., Ginsburg D. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 97:1996;232-237.
236. Barazzone C., Belin D., Piguet P.F., Vassalli J.D., Sappino A.P. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest. 98:1996;2666-2673.
237. MacKenzie T.D., Bartecchi C.E., Schrier R.W. The human costs of tobacco use. N Engl J Med. 330:1994;975-980.
238. D'Armiento J., Dalal S.S., Okada Y., Berg R.A., Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell. 71:1992;955-961.
239. Shapiro S.D. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med. 150:1994;S160-S164.
240. Hautamaki R.D., Kobayashi D.K., Senior R.M., Shapiro S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 277:1997;2002-2004.
241. Shapiro S.D. Mighty mice. Transgenic technology "knocks out" questions of matrix metalloproteinase function Matrix Biol. 15:1997;527-533.
242. Umans L., Serneels L., Overbergh L., Lorent K., Van Leuven F., Van den Berghe H. Targeted inactivation of the mouse alpha 2-macroglob ulin gene. J Biol Chem. 270:1995;19778-19785.
243. Saftig P., Hetman M., Schmal W., Weber K., Heine L., Mossmann H., Köster A., Hess B., Evers M., von Figura K., Peters C. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14:1995;3599-3608.
244. Kaharri V.M., Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol. 6:1997;199-213.
245. Bugge T.H., Kombrinck K.W., Flick M.J., Daugherty C.C., Danton M.J., Degen J.L. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell. 87:1996;709-719.
246. Drew A.F., Kaufman A.H., Kombrink K.W., Danton M.J., Daugherty C.C., Degen J.L., Bugge T.H. Ligneous conjunctivitis in plasminogen-deficient mice. Blood. 91:1998;1616-1624.
247. Shapiro R.L., Duquette J.G., Nunes I., Roses D.F., Harris M.N., Wilson E.L., Rifkin D.B. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am J Pathol. 150:1997;359-369.
248. D'Armiento J., Dicolandrea T., Dalal S.S., Okada Y., Huang M.Y., Conney A.H., Chada K. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acathosis and increases susceptibility to tumorigenesis. Mol Cell Biol. 15:1995;5732-5739.
249. Matsushima K., Taguchi M., Kovacs E.J., Young H.A., Oppenheim J.J. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol. 136:1986;2883-2891.
250. Auberger P., Sonthonnax S., Peyron J.F., Mari B., Fehlman M. A chymotryptic-type serine proteinase is required for IL-2 production by Jurkat T cells. Immunology. 70:1993;547-550.
251. Gyetko M.R., Chen G.H., McDonald R.A., Goodman R., Huffnagle G.B., Wilkinson C.C., Fuller J.A., Toews G.B. Urokinase is required for the pulmonary inflammatory response to cryptococcus neoformans. J Clin Invest. 97:1996;1818-1826.
252. Boyle M.D.P., Lottenberger R. Plasminogen activation by invasive human pathogens. Thromb Haemost. 77:1997;1-10.
253. Coleman J.L., Gebbia J.A., Piesman J., Degen J.L., Bugge T.H., Benach J.L. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell. 89:1997;1111-1119.
254. Bellaaouaj A., McCarthy R., Baumann M., Gao Z., Ley T.J., Abraham S.N., Shapiro S.D. Mice lacking neutrohpil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 4:1998;615-618.